Iron nanoparticle could light up MS brain inflammation on MRI

NCT ID NCT02511028

Completed Knowledge-focused Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 05, 2026 · Updated 8 times

Summary

This early-phase study tested whether ferumoxytol, an iron-based contrast agent, can help MRI scans better detect inflammation in the brains of people with multiple sclerosis (MS). Fourteen participants (some with MS, some healthy) received a single IV dose of ferumoxytol and had multiple 7-tesla MRI scans over six months. The goal was to see if the drug causes lasting changes in brain signals and whether it can highlight areas of inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ferumoxytol (an iron-based contrast agent given by IV)
What this could lead to: If successful, ferumoxytol could become a new way to see inflammation in the brains of people with multiple sclerosis using MRI.
What could go wrong: This is a very small, early-phase study with only 14 participants. It is testing imaging, not treatment, so it won't directly improve MS symptoms. Ferumoxytol may cause long-lasting MRI signal changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.